Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 544.0m

Basilea Pharmaceutica Valuation

Is BSLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 37.35
Fair Value
20.1% overvalued intrinsic discount
6
Number of Analysts

Below Fair Value: BSLN (CHF44.85) is trading above our estimate of fair value (CHF37.35)

Significantly Below Fair Value: BSLN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSLN?

Key metric: As BSLN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BSLN. This is calculated by dividing BSLN's market cap by their current earnings.
What is BSLN's PE Ratio?
PE Ratio7x
EarningsCHF 77.59m
Market CapCHF 544.03m

Price to Earnings Ratio vs Peers

How does BSLN's PE Ratio compare to its peers?

The above table shows the PE ratio for BSLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.6x
SANN Santhera Pharmaceuticals Holding
3.2xn/aCHF 201.0m
COPN Cosmo Pharmaceuticals
16.3x21.5%CHF 1.1b
SKAN SKAN Group
54.1x17.9%CHF 1.7b
XLS Xlife Sciences
5xn/aCHF 105.6m
BSLN Basilea Pharmaceutica
7x6.5%CHF 544.0m

Price-To-Earnings vs Peers: BSLN is good value based on its Price-To-Earnings Ratio (7x) compared to the peer average (19.6x).

Price to Earnings Ratio vs Industry

How does BSLN's PE Ratio compare vs other companies in the European Biotechs Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BSLN 7.0xIndustry Avg. 22.6xNo. of Companies4PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BSLN is good value based on its Price-To-Earnings Ratio (7x) compared to the European Biotechs industry average (25.8x).

Price to Earnings Ratio vs Fair Ratio

What is BSLN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSLN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7x
Fair PE Ratio18.7x

Price-To-Earnings vs Fair Ratio: BSLN is good value based on its Price-To-Earnings Ratio (7x) compared to the estimated Fair Price-To-Earnings Ratio (18.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 44.85
CHF 76.92
+71.5%
31.9%CHF 120.00CHF 52.00n/a6
Feb ’26CHF 40.70
CHF 77.25
+89.8%
31.6%CHF 120.00CHF 52.00n/a6
Jan ’26CHF 41.35
CHF 77.25
+86.8%
31.6%CHF 120.00CHF 52.00n/a6
Dec ’25CHF 41.70
CHF 77.25
+85.3%
31.6%CHF 120.00CHF 52.00n/a6
Nov ’25CHF 43.20
CHF 74.87
+73.3%
35.7%CHF 120.00CHF 44.20n/a6
Oct ’25CHF 45.60
CHF 73.20
+60.5%
32.8%CHF 110.00CHF 44.20n/a6
Sep ’25CHF 46.00
CHF 72.37
+57.3%
32.0%CHF 110.00CHF 44.20n/a6
Aug ’25CHF 39.75
CHF 71.20
+79.1%
30.5%CHF 105.00CHF 44.20n/a6
Jul ’25CHF 39.50
CHF 71.20
+80.3%
30.5%CHF 105.00CHF 44.20n/a6
Jun ’25CHF 43.70
CHF 70.58
+61.5%
31.9%CHF 105.00CHF 40.50n/a6
May ’25CHF 39.50
CHF 70.58
+78.7%
31.9%CHF 105.00CHF 40.50n/a6
Apr ’25CHF 37.65
CHF 69.08
+83.5%
30.6%CHF 105.00CHF 40.50n/a6
Mar ’25CHF 35.15
CHF 69.08
+96.5%
30.6%CHF 105.00CHF 40.50n/a6
Feb ’25CHF 33.05
CHF 64.38
+94.8%
24.7%CHF 85.00CHF 40.50CHF 40.704
Jan ’25CHF 35.30
CHF 70.70
+100.3%
26.5%CHF 91.00CHF 40.50CHF 41.355
Dec ’24CHF 34.95
CHF 75.68
+116.5%
19.8%CHF 91.00CHF 57.70CHF 41.704
Nov ’24CHF 35.60
CHF 73.28
+105.9%
20.1%CHF 91.00CHF 52.00CHF 43.206
Oct ’24CHF 41.00
CHF 70.44
+71.8%
21.7%CHF 91.00CHF 52.00CHF 45.607
Sep ’24CHF 48.20
CHF 70.44
+46.1%
21.7%CHF 91.00CHF 52.00CHF 46.007
Aug ’24CHF 43.85
CHF 70.44
+60.6%
21.7%CHF 91.00CHF 52.00CHF 39.757
Jul ’24CHF 42.25
CHF 67.18
+59.0%
21.0%CHF 91.00CHF 52.00CHF 39.506
Jun ’24CHF 45.90
CHF 67.18
+46.4%
21.0%CHF 91.00CHF 52.00CHF 43.706
May ’24CHF 43.20
CHF 72.07
+66.8%
20.8%CHF 91.00CHF 52.00CHF 39.506
Apr ’24CHF 50.10
CHF 74.80
+49.3%
18.4%CHF 91.00CHF 52.00CHF 37.655
Mar ’24CHF 52.40
CHF 68.98
+31.6%
26.2%CHF 91.00CHF 39.90CHF 35.156
Feb ’24CHF 49.00
CHF 73.82
+50.6%
34.7%CHF 120.00CHF 39.90CHF 33.056
Analyst Price Target
Consensus Narrative from 6 Analysts
CHF 76.92
Fair Value
41.7% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 04:57
End of Day Share Price 2025/02/20 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Basilea Pharmaceutica AG is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research